Westlind-Danielsson A, Arnerup G
NEUROTEC, Karolinska Institute, Geriatric Medicine, Novum, KFC, S-141 86 Huddinge, Sweden.
Biochemistry. 2001 Dec 11;40(49):14736-43. doi: 10.1021/bi010375c.
The concentration of beta-amyloid peptide (Abeta), x-42 or x-40 amino acids long, increases in brain with the progression Alzheimer's disease (AD). These peptides are deposited extracellularly as highly insoluble fibrils that form densities of amyloid plaques. Abeta fibrillization is a complex polymerization process preceded by the formation of oligomeric and prefibrillar Abeta intermediates. In some of our in vitro studies, in which the kinetics of intermediate steps of fibril formation were examined, we used concentrations of synthetic Abeta that exceed what is normally employed in fibrillization studies, 300-600 microM. At these concentrations, in a cell free system and under physiological conditions, Abeta 1-40 peptide (Abeta40) forms fibrils that spontaneously assemble into clearly defined spheres, "betaamy balls", with diameters of approximately 20-200 microm. These supramolecular structures show weak birefringence with Congo red staining and high stability with prolonged incubation times (at least 2 weeks) at 30 degrees C, freezing, and dilution in H(2)O. At 600 microM, they are detected after incubation for approximately 20 h. Abeta peptide 1-42 (Abeta42) lacks the ability to form betaamy balls but accelerates Abeta40 betaamy ball formation at low stoichiometric levels (1:20 Abeta42:Abeta40 ratio). Abeta42 levels above this (=10-50% w/w) impede Abeta40 betaamy ball formation. Using light (LM) and electron microscopy (EM), this study examines the gross morphology and ultrastructure of Abeta40 betaamy balls and their time course of formation, in the absence and presence of Abeta42, along with some stability measures. As spheres of a misfolded protein, betaamy balls resemble both AD Abeta senile plaques and neuronal inclusion bodies associated with other neurodegenerative diseases.
随着阿尔茨海默病(AD)病情进展,大脑中长度为x - 42或x - 40个氨基酸的β - 淀粉样肽(Aβ)浓度会升高。这些肽以高度不溶性纤维的形式在细胞外沉积,形成淀粉样斑块。Aβ纤维化是一个复杂的聚合过程,在此之前会形成寡聚体和原纤维状Aβ中间体。在我们的一些体外研究中,检测了纤维形成中间步骤的动力学,我们使用的合成Aβ浓度超过了纤维化研究中通常使用的浓度,即300 - 600微摩尔。在这些浓度下,在无细胞体系和生理条件下,Aβ1 - 40肽(Aβ40)形成纤维,这些纤维会自发组装成直径约为20 - 200微米的明确定义的球体,即“β淀粉样球”。这些超分子结构用刚果红染色显示出弱双折射,在30℃下长时间孵育(至少2周)、冷冻以及在水中稀释时具有高稳定性。在600微摩尔浓度下,孵育约20小时后可检测到它们。Aβ肽1 - 42(Aβ42)缺乏形成β淀粉样球的能力,但在低化学计量水平(Aβ42:Aβ40比例为1:20)时会加速Aβ40β淀粉样球的形成。高于此水平(=10 - 50% w/w)的Aβ42水平会阻碍Aβ40β淀粉样球的形成。本研究使用光学显微镜(LM)和电子显微镜(EM),在有无Aβ42的情况下,研究了Aβ40β淀粉样球的总体形态和超微结构、它们的形成时间进程以及一些稳定性指标。作为错误折叠蛋白的球体,β淀粉样球既类似于AD的Aβ老年斑,也类似于与其他神经退行性疾病相关的神经元包涵体。